About CRMI Company

China Regenerative Medicine International Limited (“China Regenerative Medicine”) was incorporated in the Cayman Islands and listed on the Hong Kong Stock Exchange on July 18, 2001, with stock code 8158. The main business of regenerative medicine in China is engaged in research and development of biomedical products and healthcare products and medical technology; the production and sale of tissue engineering products and their derivatives; and the sale and distribution of medical products and equipment. As a leader in the industrialization of biological tissue engineering and regenerative medicine in China, the company focuses on four major business areas, namely cell and stem cell therapy; tissue engineering; beauty and health; and medical equipment and other services. Our current production sites are located in Xi'an, Shaanxi, Shenzhen, Guangdong, Suzhou, Jiangsu, and Tianjin. Local businesses are operated by indirect wholly-owned subsidiaries Shaanxi Elskin Engineering Co., Ltd. (“Shaanxi Airskin”), Shaanxi Ruisheng Biotechnology Co., Ltd., Aokai (Suzhou) Biotechnology Co., Ltd., and Tianjin Weikai Bioengineering Co., Ltd. Shaanxi Elskin is the first private company to specialize in research and development in the field of organizational engineering in China. Shaanxi Airskin's tissue engineering products and their commercialization were confirmed as one of the key projects of the “863 Plan” of the Ministry of Science and Technology of China. The tissue-engineered skin product “Body Care” won the first prize of the National Science and Technology Progress Award in 2011, and was approved by the China Food and Drug Administration (“China Drug Administration”) as the country's first tissue-engineered skin product containing living human cells. Our plants in Xi'an and Shenzhen are responsible for developing and producing our organizational engineering products. The plant in Xi'an is mainly responsible for tissue engineering skin, that is, “body skin care” and mucous membranes and their derivatives, while the Shenzhen plant mainly provides the production and development of the bioengineered cornea “Aixin Eye”. The bioengineered cornea “Aixintong” independently developed by China Regenerative Medicine and has complete independent intellectual property rights was approved for sale by the China Drug Administration in April 2015, making it the world's first bioengineered corneal product. The Suzhou plant provides clinical-grade cell production and processing services, while the Tianjin plant mainly provides contracted technical research services and the design, manufacture and sale of pre-clinical-grade cell culture machines for relevant institutions. The Group will continue to explore high-quality medical products and technologies and focus on therapeutic innovation in regenerative medicine. In an effort to promote the development of regenerative medicine, China Regenerative Medicine will establish regenerative medicine cell therapy centers in various cities such as Suzhou and Tianjin. At the same time, China's regenerative medicine is seizing the opportunity to establish long-term partnerships with world-leading institutions on the development of cell and stem cell therapies. In 2014, China Regenerative Medicine was the first biotech company to establish a technology center for cell and stem cell therapy at Oxford University. Since the second quarter of 2015, China Regenerative Medicine has begun designing and establishing the China Stem Cell Clinical Application Center at the Hong Kong Science Park in Shatin, Hong Kong. The center will provide clinical-grade cell-related services and products. Furthermore, in the third quarter of 2015, China Regenerative Medicine began the establishment of 5 adult tissue cell banks in the area near existing production facilities and in Hong Kong. Through cooperation with world-class institutions such as the University of Oxford and leading universities in Hong Kong, we have obtained relevant expertise from them, and provided support to hospitals across the country for the application of cell and stem cell therapy at the centers described above. Regenerative medicine in China will continue to explore new fields of human life science and lead global medical innovation. The Group will continue to strive to use its resources and expertise to promote product development, commercialize products and develop market potential. While improving human health and life is the mission China regenerative medicine has always adhered to, we will also strive to enhance long-term shareholder value.